ArticlePathogens and global health2015
Late diagnosis: a factor associated with death from visceral leishmaniasis in elderly patients.
Article in Pathogens and global health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Epidemiological transitions of Visceral Leishmaniasis in G20 countries: A 33-year retrospective joinpoint and demographic decomposition analysis with 20-year ARIMA projections.PLoS neglected tropical diseases · 2026Article
- Global, regional, and national age-gender-specific trends, decomposition analysis, and Bayesian age-period-cohort modelling for projections of the burden of leishmaniasis: A population-based ecological study.Current research in parasitology & vector-borne diseases · 2026Article
- Temporal and spatial analysis of visceral leishmaniasis in Brazil, by age group and sex: an ecological study, 2013-2022.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2025Article
- Demographic and Clinical Features of Visceral Leishmaniasis in Chad: A Prospective Cross-Sectional Survey.The American journal of tropical medicine and hygiene · 2024Article
- rMELEISH: A Novel Recombinant Multiepitope-Based Protein Applied to the Serodiagnosis of Both Canine and Human Visceral Leishmaniasis.Pathogens (Basel, Switzerland) · 2023Article
- Case Report: The First Case Report of Visceral Leishmaniasis in Cambodia.The American journal of tropical medicine and hygiene · 2022Article
- Enablers and hindrances to health promotion and disease prevention practices among healthcare workers in Nelson Mandela Bay Municipality, South Africa.Preventive medicine reports · 2021Article
- Space-time risk cluster of visceral leishmaniasis in Brazilian endemic region with high social vulnerability: An ecological time series study.PLoS neglected tropical diseases · 2021Article
- Premature deaths by visceral leishmaniasis in Brazil investigated through a cohort study: A challenging opportunity?PLoS neglected tropical diseases · 2019Article
- Where, when, and how the diagnosis of human visceral leishmaniasis is defined: answers from the Brazilian control program.Memorias do Instituto Oswaldo Cruz · 2019Article
- Imported leishmaniasis in Sweden 1993-2016.Epidemiology and infection · 2018Article
- Visceral leishmaniasis in a Brazilian endemic area: an overview of occurrence, HIV coinfection and lethality.Revista do Instituto de Medicina Tropical de Sao Paulo · 2018Article
- Hematological Characteristics of Yemeni Adults and Children with Visceral Leishmaniasis. Could Eosinopenia be a Suspicion Index?Mediterranean journal of hematology and infectious diseases · 2017Article
- Risk Factors of Inpatients Mortality of Visceral Leishmaniasis, Khartoum State, Sudan.Journal of global infectious diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVisceral leishmaniasis (VL) is among the seven global endemic diseases assigned a high priority by the World Health Organization. In Latin America, most cases occur in Brazil. Despite the availability of intensive treatment resources and protocols for specific treatment, lethality rates for VL have increased in several regions in the country over the past 10 years, particularly in patients under one and over 50 years of age. As the growth of the elderly population accelerates in Brazil, VL poses a greater challenge to public health. Given the scarcity of studies addressing the disease in this age group, the purpose of this study was to identify factors associated with VL lethality among the elderly. METHODS/KEY
findingsThis analytical, cross-sectional epidemiological study comprised 80 elderly patients who sought treatment at the teaching hospital of the Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil, in the period 2000-2013.Clinical, laboratory and treatment variables were investigated from records of elderly patients with VL diagnosis confirmed by at least one laboratory test positive (culture for parasite or direct parasitological examination; reactive immunofluorescence; immunochromatographic test with recombinant antigens) or patients without laboratory confirmation who lived in endemic areas and responded favorably to therapeutic trial, as defined by the Brazilian Ministry of Health. Of the 80 patients included, 78 tested positive to at least one exam; in two cases, diagnosis was based on clinical and epidemiological criteria. The lethality rate was 20%. Multivariate analysis revealed an association between death and time elapsed from symptom onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.